학술논문

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Document Type
Article
Source
In: The Lancet. (The Lancet, 25 September 2021, 398(10306):1157-1169)
Subject
Language
English
ISSN
1474547X
01406736